Principal Financial Group Inc Ocugen, Inc. Transaction History

Principal Financial Group Inc

$162 Billion
Q1 2024

A detailed history of Principal Financial Group Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 59,354 shares of OCGN stock, worth $97,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,354

Previous 68,489 13.34%

Holding current value

$97,340

Previous $39,000 148.72%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$0.5 - $1.83 $4,567 - $16,717	-9,135 Reduced 13.34%	59,354 $97,000
Q4 2023 Feb 07, 2024	BUY	$0.36 - $0.57 $2,422 - $3,834	6,728 Added 10.89%	68,489 $39,000
Q2 2023 Aug 07, 2023	BUY	$0.45 - $0.88 $491 - $960	1,092 Added 1.8%	61,761 $33,000
Q1 2023 May 09, 2023	SELL	$0.82 - $1.33 $3,662 - $5,941	-4,467 Reduced 6.86%	60,669 $51,000
Q4 2022 Feb 09, 2023	BUY	$1.11 - $1.87 $12,096 - $20,379	10,898 Added 20.09%	65,136 $84,000

Q3 2022 Nov 09, 2022	SELL	$1.75 - $3.1 $2,439 - $4,321	-1,394 Reduced 2.51%	54,238 $96,000
Q2 2022 Aug 10, 2022	SELL	$1.83 - $3.45 $1,268 - $2,390	-693 Reduced 1.23%	55,632 $126,000
Q1 2022 May 09, 2022	BUY	$2.34 - $4.72 $2,655 - $5,357	1,135 Added 2.06%	56,325 $186,000
Q4 2021 Feb 09, 2022	SELL	$4.38 - $15.67 $91,506 - $327,377	-20,892 Reduced 27.46%	55,190 $251,000
Q3 2021 Nov 09, 2021	BUY	$6.36 - $8.51 $19,964 - $26,712	3,139 Added 4.3%	76,082 $546,000
Q2 2021 Aug 10, 2021	BUY	$5.52 - $15.68 $402,645 - $1.14 Million	72,943 New	72,943 $585,000

Others Institutions Holding OCGN

# of Institutions

Shares Held

32.8M

Call Options Held

518K

Put Options Held

345K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $355M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Ocugen, Inc. Transaction History